Skip to main content

Table 1 Demographic and baseline clinical characteristics

From: Natalizumab in the pediatric MS population: results of the Italian registry

  Mean (SD)
Age at MS onset (years) 12.9 (2.7)
Pre-NA disease duration (months) 25.6 (23.3)
Age at NA initiation (years) 14.7 (2.4)
Weight (Kg) 62.0 (13.3)
Height (cm) 163.5 (12.3)
Number of relapses prior NA initiation 4.0 (2.2)
Number of relapses in the year prior NA initiation 2.3 (1.3)
Number of Gd + MRI lesions prior NA initiation 3.3 (4.4)
EDSS at NA initiation 2.6 (1.3)